HALOZYME THERAPEUTICS, INC.
HALO evidence brief
What we can confirm
- BioSniper Score:
- 4.0 / 10
- Market Cap:
- $12.17B
- Lead Asset:
- xyosted (Approved)
What it means
What to watch
Prepared research question
What matters most for HALO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HALO
Halozyme Therapeutics (HALO) is a biopharmaceutical drug delivery company that develops and licenses its ENHANZE® technology to enable subcutaneous delivery of injectable biologics, generating revenue through royalties and milestones from partnered products.
Key risk: High debt burden
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial · 1 catalyst for HALOZYME THERAPEUTICS, INC..
Halozyme Therapeutics (HALO) is a biopharmaceutical drug delivery company that develops and licenses its ENHANZE® technology to enable subcutaneous delivery of injectable biologics, generating revenue through royalties and milestones from partnered products.
- Reported Q2 CY2026 revenue of $481M, up 47.7% year-over-year [news · 2026-08-11].
- Cash and equivalents of $163.1M as of 2026-06-30 [sec].
- Full-year 2026 revenue guidance midpoint of $1.87B, 5.9% above analyst estimates [news · 2026-08-11].
- Total debt of $2,146.7M as of 2026-06-30 [sec].
- Acquired Surf Bio, Inc. in December 2025 to add biologic hyperconcentration technology [news · 2026-01-28].
What works
- Revenue growth is strong, with Q2 2026 sales up 47.7% year-over-year to $481M [news · 2026-08-11].
- Multiple partnered products using ENHANZE have received regulatory approvals in major markets (e.g., RYBREVANT FASPRO in China and Japan, Opdivo SC in Europe) [sec · filed 2026-03-23].
- The company has a diversified pipeline with new programs (e.g., sabirnetug Phase 1 study) and a recent acquisition (Surf Bio) expanding its technology platform [sec · filed 2026-03-23; news · 2026-01-28].
What to weigh
- Total debt is substantial at $2,146.7M as of 2026-06-30, far exceeding shareholders' equity of $143.5M [sec].
- The company's revenue is heavily dependent on partnered products and milestone payments, which can be lumpy and subject to partner decisions [sec · filed 2026-03-23].
- A key patent (NDA208088) for testosterone undecanoate is set to expire on 2030-11-30, which could affect future revenue from that product [catalyst].
From the filings
Quoted directly from source documents.
Catalyst timeline
- 2030-11-30 · Patent_Expiry · TESTOSTERONE UNDECANOATE — Patent_Expiry: NDA208088 — Expiration of this patent could reduce revenue from the testosterone undecanoate product.
Risks & what to watch (3)›
Key risks
- High debt burden — Total debt of $2,146.7M far exceeds equity of $143.5M as of 2026-06-30 [sec].
- Patent expiry risk — Patent for testosterone undecanoate (NDA208088) expires 2030-11-30, potentially reducing future revenue [catalyst].
- Partner dependency — Revenue relies on partner milestones and approvals; partner decisions can cause variability [sec · filed 2026-03-23].
What to watch
- Upcoming Phase 3 study start for XYOSTED® in adolescent hypogonadism (started 2025-03-07) [catalyst].
- Patent expiry of NDA208088 on 2030-11-30 and its impact on revenue [catalyst].
- Integration and pipeline progress from the Surf Bio acquisition [news · 2026-01-28].
- Continued regulatory decisions for partnered ENHANZE products in new markets [sec · filed 2026-03-23].
Sources: Catalysts · News · SEC filings · Generated October 13, 2026 · How we verify sources →
Run HALOZYME THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available HALOZYME THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 16.96 · 3% dilution
Lead: Approved
1 candidate
1 upcoming, next in ~1508d
0 buys · 40 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 15.7%
- Days to cover
- 10.3
- Shares short
- 14,381,741
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HALO short interestGovernance
Frequently asked questions
What is the AI investment thesis for HALOZYME THERAPEUTICS, INC.?
Halozyme Therapeutics (HALO) is a biopharmaceutical drug delivery company that develops and licenses its ENHANZE® technology to enable subcutaneous delivery of injectable biologics, generating revenue through royalties and milestones from partnered products.
What is HALOZYME THERAPEUTICS, INC.'s lead drug candidate?
HALOZYME THERAPEUTICS, INC.'s most advanced tracked candidate is xyosted (Approved).
What is HALOZYME THERAPEUTICS, INC.'s next catalyst?
HALOZYME THERAPEUTICS, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA208088" — expected November 30, 2030.
Who is the CEO of HALOZYME THERAPEUTICS, INC.?
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. is the chief executive officer of HALOZYME THERAPEUTICS, INC. (HALO).
Where is HALOZYME THERAPEUTICS, INC. headquartered?
HALOZYME THERAPEUTICS, INC. (HALO) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.